Literature DB >> 30701632

Dorsal Root Ganglion Stimulation Is Paresthesia-Independent: A Retrospective Study.

Paul Verrills1, Bruce Mitchell1, David Vivian1, William Cusack2, Jeffery Kramer2.   

Abstract

INTRODUCTION: Neuromodulation is an important tool for achieving pain relief in otherwise-intractable neuropathic pain conditions. Dorsal root ganglion (DRG) stimulation, in which primary sensory neurons are stimulated prior to their entry into the spinal canal, provides treatment with high levels of dermatomal specificity and can provide advantages compared to conventional spinal cord stimulation. Although DRG stimulation can produce perceptible paresthesias, many patients operate their systems at subthreshold amplitudes that do not elicit this sensation. Pain relief both with and without paresthesia was investigated in this retrospective analysis.
MATERIALS AND METHODS: A retrospective review of all qualifying permanent DRG stimulation systems at a single center over more than a three-year period was completed. Pain (0-10 numeric rating scale) was assessed at baseline, at the end of the trial, and after three, six, and twelve months of treatment. Patients were categorized based on their usage of the stimulator at amplitudes that either did or did not produce paresthesias.
RESULTS: Of the 39 patients, 34 (87%) reported having no-paresthesias at any of the follow-up visits. Average pain relief was 73.9% after the trial period and 63.1% after 12 months of treatment. The responder rate (50% or better pain relief) after three months of treatment was more than 80%. Exploratory subgroup analyses showed that similar degrees of pain relief were achieved in numerous body regions and with various pain etiologies. The five patients who reported paresthesias during treatment had pain relief similar to those of the group that did not experience paresthesias. DISCUSSION: Clinically significant and sustained pain relief over more than a period of 12 months was achieved with DRG stimulation programmed at amplitudes below the perceptual level. Thus, the reported analgesia was paresthesia-independent. That good clinical outcomes were observed independent of the generation of paresthesia in DRG stimulation suggests several mechanisms of action, including the inhibition of supraspinal regions involved in somatic paresthesia sensation. The retrospective results presented here posit that future prospective study of DRG stimulation delivered at below the threshold of perceptible paresthesias is warranted.
© 2019 International Neuromodulation Society.

Entities:  

Keywords:  Chronic pain; dorsal root ganglion stimulation; neuromodulation; neuropathic pain; pain relief; paresthesia coverage; spinal cord stimulation

Mesh:

Year:  2019        PMID: 30701632     DOI: 10.1111/ner.12921

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  5 in total

1.  [ANA- 12 inhibits spinal inflammation and alleviates acute and chronic pain in rats by targeted blocking of BDNF/TrkB signaling].

Authors:  J Zhao; H Yang; Z Wang; H Zhu; M Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

2.  Blocking peripheral drive from colorectal afferents by subkilohertz dorsal root ganglion stimulation.

Authors:  Longtu Chen; Tiantian Guo; Shaopeng Zhang; Phillip P Smith; Bin Feng
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

Review 3.  Spinal Cord Stimulation as Treatment for Cancer and Chemotherapy-Induced Pain.

Authors:  Breanna L Sheldon; Jonathan Bao; Olga Khazen; Julie G Pilitsis
Journal:  Front Pain Res (Lausanne)       Date:  2021-08-24

4.  Analgesic dorsal root ganglionic field stimulation blocks conduction of afferent impulse trains selectively in nociceptive sensory afferents.

Authors:  Dongman Chao; Zhiyong Zhang; Christina M Mecca; Quinn H Hogan; Bin Pan
Journal:  Pain       Date:  2020-12       Impact factor: 7.926

Review 5.  Dorsal Root Ganglion (DRG) and Chronic Pain.

Authors:  Amnon A Berger; Yao Liu; HarLee Possoit; Anna C Rogers; Warner Moore; Kyle Gress; Elyse M Cornett; Alan David Kaye; Farnad Imani; Kambiz Sadegi; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Anesth Pain Med       Date:  2021-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.